## Cochrane meetings are unaffordable

and Cochrane cannot depend on

taxpayers to subsidise their activities

#### The Problem

Cochrane is a large organisation with groups with widely dispersed teams. **Cochrane Schizophrenia** is no exception with the editorial base in the UK–split between England and Scotland, editors in 7 nations and over 1300 reviewers in 41 countries. Employers, funders and Cochrane expect training and support – and some face-to-face time is necessary for this. Core funding, from UK's NIHR, does include support for meeting.



Aim: To investigate annual Cochrane meeting costs.


### Methods

Crude estimates of costs (mostly registration, travel and accommodation) for only the core

### Conclusions

UK funding for Cochrane work is in a privileged position with [for Cochrane Schizophrenia] around £3000/ annum for travel and meetings. With a local Colloquium, 2018-19 should have been a year to be within budget. It was not. Expenditure of public funds in this way is unsustainable. Cochrane has considerable resource and supports its staff to travel and attend necessary meetings. For some meetings Cochrane grants one free place per CRG. Cochrane income remains dependent on investment of public funds and yet the necessary networking depends on yet more taxpayer investment. Something has to give.

Cochrane Review Group (CRG) team (3 staff and Co-eds) for financial year 2018-19.



# The financial cost of Cochrane meetings: an inexpensive[!] year in the UK (2018-19)

Clive E Adams, Claire Irving, Rebecca Syed Sheriff, Pablo Roson